Clinical Trial Update: Switch From Tenofovir to Raltegravir for Low Bone Mineral Density [Phase 4]

View source ↗

Summary

Phase 4 trial results examining switching from tenofovir to raltegravir in people with HIV and low bone mineral density (osteopenia/osteoporosis).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection
• Osteopenia
• Osteoporosis

Drugs mentioned

• Raltegravir (raltegravir)
• Viread (tenofovir disoproxil fumarate)

Snippet

Sponsor: St Vincent's Hospital, Sydney | Conditions: HIV, Osteopenia | Phase 4 | Status: COMPLETED | Results posted: 2015-06-12